|
KR102208505B1
(ko)
|
2012-12-11 |
2021-01-27 |
앨버트 아인슈타인 컬리지 오브 메디신 |
고처리량 수용체:리간드 확인을 위한 방법
|
|
SG11201700514SA
(en)
*
|
2014-07-21 |
2017-02-27 |
Delinia Inc |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
SI3482766T1
(sl)
|
2014-08-11 |
2020-09-30 |
Delinia, Inc. |
Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
|
|
MX2017012966A
(es)
|
2015-04-10 |
2018-06-06 |
Amgen Inc |
Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CN109071623B
(zh)
*
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
CA3019005A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
AU2017359172A1
(en)
*
|
2016-11-08 |
2019-05-16 |
Delinia, Inc. |
IL-2 variants for the treatment of autoimmune diseases
|
|
WO2018112069A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
|
MX2019007611A
(es)
|
2016-12-22 |
2020-07-29 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
AU2018234628B2
(en)
|
2017-03-15 |
2023-07-20 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
EP3604538A4
(en)
*
|
2017-03-29 |
2020-12-30 |
University of Miyazaki |
LONG-ACTING ADRENOMEDULLINE DERIVATIVE
|
|
CN111010866A
(zh)
|
2017-05-24 |
2020-04-14 |
潘迪恩治疗公司 |
靶向免疫耐受性
|
|
SG11202004581PA
(en)
|
2017-11-21 |
2020-06-29 |
Univ Leland Stanford Junior |
Partial agonists of interleukin-2
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
JP7250790B2
(ja)
*
|
2017-12-06 |
2023-04-03 |
パンディオン・オペレーションズ・インコーポレイテッド |
Ｉｌ－２ムテインおよびその使用
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
WO2019131964A1
(ja)
|
2017-12-27 |
2019-07-04 |
協和発酵キリン株式会社 |
Ｉｌ－２改変体
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019144309A1
(en)
*
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
WO2019147837A2
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine fusion proteins
|
|
US11534479B2
(en)
|
2018-02-16 |
2022-12-27 |
Iltoo Pharma |
Use of interleukin 2 for treating Sjögren's syndrome
|
|
TW202513581A
(zh)
|
2018-03-28 |
2025-04-01 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
|
EP3552738B1
(en)
*
|
2018-04-12 |
2024-07-31 |
Sandvik Machining Solutions AB |
A method of producing an additive manufactured object
|
|
CN112638406B
(zh)
|
2018-06-22 |
2025-04-22 |
科优基因公司 |
白介素-2变体及其使用方法
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
EP3827079A1
(en)
|
2018-07-25 |
2021-06-02 |
Askgene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
CA3172359A1
(en)
|
2018-08-06 |
2020-02-13 |
Medikine, Inc. |
Il-2 receptor binding compounds
|
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
AU2019409196A1
(en)
*
|
2018-12-21 |
2021-06-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
Human interleukin-2 variant or derivative thereof
|
|
CN120157766A
(zh)
|
2019-02-01 |
2025-06-17 |
瑞泽恩制药公司 |
抗IL2受体γ抗原结合蛋白
|
|
WO2020168024A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
CA3129834A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
|
CN114679909A
(zh)
|
2019-05-20 |
2022-06-28 |
潘迪恩运营公司 |
MAdCAM靶向的免疫耐受
|
|
WO2020252264A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
US20220306714A1
(en)
*
|
2019-08-12 |
2022-09-29 |
AskGene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
|
CA3160466A1
(en)
|
2019-11-05 |
2021-05-14 |
Medikine, Inc. |
Dual il-2r and il-7r binding compounds
|
|
US11718654B2
(en)
|
2019-11-05 |
2023-08-08 |
Medikine, Inc. |
IL-2R-βγ binding compounds
|
|
JP2023505590A
(ja)
*
|
2019-12-12 |
2023-02-09 |
イルトゥー・ファルマ |
インターロイキン２キメラ構築物
|
|
WO2021127495A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
|
US11746139B2
(en)
|
2020-02-03 |
2023-09-05 |
Medikine, Inc. |
IL-7Rαγc binding compounds
|
|
BR112022014401A2
(pt)
|
2020-02-03 |
2022-11-16 |
Medikine Inc |
Ligante de il-7r-alfa, composto, composição farmacêutica e ácido nucleico
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
US11028132B1
(en)
|
2020-04-07 |
2021-06-08 |
Yitzhak Rosen |
Half-life optimized linker composition
|
|
MX2022013208A
(es)
|
2020-05-12 |
2022-11-14 |
Cue Biopharma Inc |
Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
|
|
IL298136A
(en)
|
2020-05-13 |
2023-01-01 |
Bonum Therapeutics Inc |
Preparations of protein complexes and methods of using them
|
|
KR20230060514A
(ko)
*
|
2020-09-01 |
2023-05-04 |
다케다 야쿠힌 고교 가부시키가이샤 |
인터루킨-2 뮤테인 및 이의 용도
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
MX2023004598A
(es)
|
2020-10-23 |
2023-06-29 |
Asher Biotherapeutics Inc |
Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
|
|
IL302114A
(en)
|
2020-10-29 |
2023-06-01 |
Bristol Myers Squibb Co |
Fusion proteins for the treatment of disease
|
|
WO2022100684A1
(zh)
|
2020-11-13 |
2022-05-19 |
江苏恒瑞医药股份有限公司 |
一种包含人白细胞介素2变体或其衍生物的药物组合物及其用途
|
|
US12098178B2
(en)
|
2020-12-04 |
2024-09-24 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
IL304365B2
(en)
*
|
2021-03-31 |
2025-04-01 |
Hanmi Pharmaceutical Co Ltd |
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
|
|
IL307481A
(en)
|
2021-04-09 |
2023-12-01 |
Selecta Biosciences Inc |
Synthetic nanocarriers containing an immune system suppressor combined with IL-2 receptor agonists with high affinity for increasing immune tolerance
|
|
JP2024533848A
(ja)
|
2021-10-06 |
2024-09-12 |
イルトゥー・ファルマ |
炎症組織へのターゲティング特異性を備えるインターロイキン２キメラコンストラクト
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20230263906A1
(en)
|
2022-01-10 |
2023-08-24 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
|
WO2023172628A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
|
US20230372535A1
(en)
|
2022-03-25 |
2023-11-23 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US11999771B2
(en)
|
2022-04-07 |
2024-06-04 |
Medikine, Inc. |
IL-7Rαγc ligand immunoglobulin fusion proteins
|
|
WO2023196566A1
(en)
|
2022-04-08 |
2023-10-12 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
|
CN115322260A
(zh)
*
|
2022-06-13 |
2022-11-11 |
杭州高田生物医药有限公司 |
能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
|
|
EP4587043A1
(en)
|
2022-09-12 |
2025-07-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Interleukin-2 for use in treating autism spectrum disorder
|
|
WO2024118771A1
(en)
|
2022-11-30 |
2024-06-06 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2024229380A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
|
|
WO2024229350A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
|
|
WO2024229432A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
WO2024229370A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Compositions and methods for treating gvhd
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|